New Cardiovascular Company Emerges from Stealth Mode

Reprieve Cardiovascular recently emerged from stealth mode after raising $42 million in series A financing.

The Milford, MA-based company is developing a system intended to personalize decongestion management and remove excess fluid to improve patient outcomes and prevent hospital readmissions. The Reprieve System monitors physiological parameters such as urine output to deliver personalized diuretic dosing and fluid replacement for patients with acute decompensated heart failure (ADHF).